VILLEPINTE, France, November 15, 2016 /PRNewswire/ --
In 90 years the Group has built a success story fueled by innovation and international growth
Guerbet(FR0000032526 GBT), the global specialist in contrast agents and solutions for medical imaging, today celebrates its 90th year with all its 2,600 employees and stakeholders.
A year after doubling in size, following a major acquisition in the United States, the Group continues to grow as one of the leading players in medical imaging worldwide. The Group offers a full range of medical solutions and services - in CT scan, MRI and Interventional Radiology - ongoing investment in innovation and its production capacities, in addition to a network of subsidiaries and partners that ensure a presence in all the principal global markets.
A pioneer and a player in imaging of the future
Although the history of Guerbet dates back to 1901, with the discovery by Marcel Guerbet of the world's first iodinated contrast agent, the official creation of the pharmaceutical company dates from 15 November 1926. In 1965 it became SA Laboratoires André Guerbet. From a headcount of 150 at that time, its staff grew to 1,000 in 1990, 1,500 in 2015 and 2,600 today, following the acquisition of Mallinckrodt's "Contrast Media and Delivery Systems" business, finalized a year ago. With this acquisition Guerbet has reached a critical size in each segment and geographical zone with the ambition of entering the world's top three.
From a business essentially focused on France in the early 1960s, Guerbet developed its international distribution network greatly from the 1970s onwards. Thirty years ago precisely, in 1986, Guerbet entered the stock market (on the Paris Stock Exchange second market) to bolster its development. Since 2005 Guerbet has undertaken a wide-ranging program of industrial site modernization: € 215 million have been devoted to this to ensure the long-term security of its jobs and to bolster its global growth strategy.
Today, Guerbet is truly, an international group, with 83% of its sales generated outside France and with four growth drivers: contrast agents for MRI, contrast agents for X-ray imaging, Interventional Radiology and Theranostics and Imaging Solutions and Services, including medical devices such as injectors.
The video illustrating our 90 years of history can be seen at the following link: http://www.guerbet.com/90-years-of-passion.html
An exceptional industrial adventure
The company announced the celebration of Guerbet's 90th anniversary at the French Radiology Congress (Journées Francophones de Radiologie), held in Paris from 14 to 17 October, where a fresco featuring the outstanding dates in Guerbet's history was unveiled in the presence of the President of the French Radiology Society. The "90 years of passion" banner is a reflection of the Guerbet teams' strong commitment to serving diagnostic and interventional imaging to enhance patient prognosis and quality of life.
In line with this celebration Guerbet's sites worldwide will be organizing events associating their employees and their external audiences over the coming months.
Campaign to follow on Twitter: @GuerbetGroup, #Guerbet90
Yves L'Epine, Guerbet CEO: "Guerbet, which has already been through many turning points, is currently experiencing a key period in its history. It is both particularly exciting and demanding time for our teams. We are in the process of successfully integrating our major acquisition to build a new global leader in medical imaging which is innovative and respectful of all its partners.
More than ever, we are driven to offer indispensable solutions for diagnostic and interventional imaging all over the world. Faced with the challenges of aging, the development of chronic diseases and certain cancers that remain difficult to treat, medical imaging opens up an exceptional range of responses which augur well for great progress for patients."
Guerbet is a pioneer in the contrast agent field, with 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on Euronext Paris (Segment B - Mid Caps) and generated €789 million in pro forma revenue in 2015.
For more information about Guerbet, please visit http://www.guerbet.com